Brief: Implantica Expects FDA Feedback On Module 3 In Autumn
24/06/2025 07:50
June 24 (Reuters) - Implantica AG 8IM1q.F: IMPLANTICA SUBMITS THE LAST AND FINAL MODULE 3 OF THE FDA PMA APPLICATION FOR REFLUXSTOP® FOR US MARKET APPROVAL IMPLANTICA AG - FDA FEEDBACK ON MODULE 3 EXPECTED IN AUTUMN Source text: ID:nPre8n924a Further company coverage: [8IM1q.F] ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on Implantica AG
See all newsBrief: Implantica Q1 Operating Loss At EUR 3.9 Mln
Brief: Implantica Gives Final Response To FDA For PMA Application
Brief: Implantica Announces Adoption Of Refluxstop At Careggi University Hospital
Brief: Implantica - FDA Provides Feedback On Refluxstop PMA Module 3
Brief: Implantica Says FDA Provides Favorable Feedback On Refluxstop Pma Module 3